Latest high-throughput screening Stories
SAN RAMON, Calif., Jan. 5, 2011 /PRNewswire/ -- Odyssey Thera, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 7,855,167.
HAMILTON, N.J., Jan.
BellBrook Labs announced today that they have been awarded a fourth U.S. patent for their innovative line of Transcreener® HTS Assay kits. This new patent, U.S.
Using an automated screening technique developed by pharmaceutical companies to find new drugs, a team of researchers from UC San Diego and three other research institutions has discovered a molecule with the most potent effects ever seen on the biological clock.
DALLAS, November 12, 2010 /PRNewswire/ -- The 'Top 10 drug discovery technologies (http://www.marketsandmarkets.com/Market-Reports/drug-discovery-41.html) - strategic analysis and global forecasts (2010 to 2015)' analyzes the top 10 drug discovery technologies with respect to market drivers, opportunities and trends in the diverse geographical regions including North America, Europe, Asia and rest of the world. Browse market data tables and in-depth TOC on Top 10 drug discovery...
BellBrook Labs Develops New High Content Assay to Explore Tumor Cell Invasion in 3D Matrix BellBrook Labs has developed a high-content tumor Cell Invasion Assay by expanding the capability of its proprietary iuvoâ„¢ Microconduit Array platform to assess three dimensional cell movement through extracellular matrix.
Scientists at The Scripps Research Institute have designed a new molecular test that will allow researchers to look for potential drugs targeting a human metabolic enzyme believed to stimulate the appetite and play a role in diabetes.
SUNNYVALE, Calif., Sept.
PARIS, July 19 /PRNewswire-FirstCall/ -- Cellectis bioresearch, a specialist in genome customization and a subsidiary of Cellectis (Alternext: ALCLS), today announced the publication of a scientific study describing a novel method, based on meganuclease-driven targeted integration, for the generation of stable cell lines compatible with high throughput screening (HTS)(1).
SEATTLE, June 29 /PRNewswire-FirstCall/ -- Omeros Corporation (Nasdaq: OMER) today announced that it has successfully identified compounds that interact with three orphan G protein-coupled receptors (GPCRs) linked to cancer, metabolic disorders and appetite control.
- A poem in which the author retracts something said in an earlier poem.